At a glance
- Originator Pfizer
- Class Antibacterials; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 04 Aug 1998 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 29 May 1996 Preclinical development for Bacterial infections in USA (Unknown route)